The 10th Annual International Congress of Vaccine-2021 (WCV-2021)

About WCV-2023

　The World Congress of Vaccines-2023 (WCV-2023) will take place during April 25-29, 2023 in Dalian, China. WCV is an international event which aims to be the most comprehensive vaccine congress where discoveries meet opportunities, innovators meet developers, and science translates into business. The conference will provide communications, education and networking opportunities for scientists engaged in vaccine whether in academia, biotech or industry. Attendees will hear world-class speakers discussing the latest technologies, challenges and opportunities facing the vaccines field.

Highlights of the Conference

● A Plenary Forum from a Panel of Leading Experts in Vaccine Field

● Hear and Discuss the Most Exciting Research Discoveries in Vaccine Field with 100+ Oral Presentations

● Network with Senior Scientists, Executives and Others over 400 Scientific and Business Sessions

● Look for a Job, Fellowship, Postdoctoral Position, or New Collaborator

● Visit over 40 Commercial and Nonprofit Exhibits Offering New Products and Services

● Kinds of Tech Tours to Famous Science Spots & Historical Sites in Dalian

Programmed Chapters at a Glance

Theme 1：Plenary Conference
Focus 1: New Era of Next Generation Vaccines
- Opening Ceremony- Keynote Forum: Leadership for Vaccine Development
Theme2: Parallel Forums
Track 1: A Fascinating World of Vaccine Innovations
Track 2: Universal Influenza & Other Anti-Infectious Vaccines
Track 3: New Horizon of Next Generation Critical Illness Vaccines
Track 4: Non-Human Vaccines
Track 5: Vaccine Clinical Trials, Safety and Management

Renowned Speakers of Previous Events

Dr. Istvan Toth, Professor, University of Queensland, Australia	Dr. Duncan D. Adams, Director, University of Otago, New Zealand	Dr. Trent Carrier, Chief Business Officer, Biologics Consulting Group Inc, USA
Dr. Steffen Nock, VP & Global Head of Biologic, Teva Pharmaceuticals, Germany	Dr. George Chryssomalis, Vice President, R&D Strategy, Global Research & Development, Acting Head R&D China , Sanofi Pasteur, France	Dr. Bruce Beutler 2011 Nobel Prize in Physiology or Medicine
Dr. Theodore F. Tsai Senior VP Novartis Vaccines USA	Dr. W. Ripley Ballou Vice President GlaxoSmithKline Biologicals Belgium	Dr. Giulio Tarro, Professor, D. Cotugno Hospital, Italy
Dr. Anton Dormer, President, Dormer-Owusu BioInstitute, Inc., USA	Dr. Stanley Chang, Chief Executive Officer, Medigen Biotechnology Corp, Taiwan	Dr. Nikolai Petrovsky, Director Vaxine Pty Ltd, Australia
Dr. Roman Prymula, Chairman, Czech Immunisation Society, The Czech Republic	Dr. Ralf Ostendorp, Vice President, Protein Sciences, MorphoSys AG, Germany	Dr. Grant Shimamoto, Senior Scientist, Amgen, USA
Dr. Myron Arlen, CEO and President, Neogenix Oncology Inc., USA	Dr. Michael A. Swit, Vice President, The Weinberg Group Inc., USA	Dr. Zhi Liu, Professor, University of North Carolina, USA
Dr. Giulio F. Tarro, Adjunct Professor, Temple University, Italy	Dr. Jishu Shi, Professor, Kansas State University, USA	Dr. Frederic J. Deschamps, Professor, Department of Occupational Health, France
Dr. Hossein A Ghanbari, CEO, Panacea Pharmaceuticals, Inc, USA	Dr. Michel Klein, Biochemistry Professor and CEO IRICoR, Institute for Research In Immunology and Cancer, Université de Montréal, Canada	Dr. Richard L Amoroso, Director, Noetic Advanced Studies Institute, Physics Lab, USA
Dr. Young Chul Sung, Professor, Pohang University of Science and Technology, CEO and Chairman, Genexine co., Korea	Dr. Martin Scholz, CSO, LEUKOCARE AG, Germany	Dr. Andrew Potter, CSO Pan-Provincial, Canada
Dr. Michael Vajdy, Co-Founder & Chief Scientific Officer, EpitoGenesis, Inc, USA	Dr. Hongzhou Lu, Director, Shanghai Public Health Clinical Center, China	Dr. Yoshinori Hayakawa, Professor, Toin University of Yokohama, Japan
Dr. Dionisio Jose Herrera Guibert, Director, Training Programs in Epidemiology and Public Health Interventions Network (TEPHINET), USA	Dr. Lilin Ye, Professor, Third Miliatary Medical University, USA	Dr. Luis Martin, Chief Science Officer, PREVENT, Canada
Dr. Qing Zhu, Professor, Institute of Materia Medica, CAMS/PUMC, China	Dr. Xin Dong Guo, Professor, Beijing University of Chemical Technology, China	Dr. Suraiya Rasheed, Professor & Director, Keck School of Medicine, University of Southern California, USA
Dr. Alicja E. Grzegorzewska, Professor, Poznan University of Medical Sciences, Poland	Dr. Fu Shi Quan, Professor, Kyung Hee University, Seoul Korea	Dr. Juan Carlos Vazquez Chagoyan, Professor, Universidad Autanoma del Estado de Mexico, Mexico
Dr. Yung Chang, Professor, Arizona State University, USA	Dr. Lutsch Charles, Chief Scientific Officer, Shantha Biotechnics Ltd ( A Sanofi Company), France	Dr. Priyabrata Pattnaik, Director Asia Vaccine Initiative, Merck Millipore, Singapore
Dr. Michael Li, Vice President of R&D, RJ Bio Process (Suzhou) Company Limited, China	Dr. Francois Bertrand, Asia Pacific Technical Development & Marketing Manager, SEPPIC, China	Dr. Aizhen Guo, Professor, College of Veterinary Medicine, Huazhong Agricultural University, China
Dr. Shyan-Song Chiou, Professor, National Chung Hsing University, Taiwan	Dr. T.-C. Wu, Professor, The Johns Hopkins Medical Institutions, USA	Dr. Vincent G. Brichard Senior VP & Head GlaxoSmithKline Biologicals Belgium
Dr. Shou-Bai Chao Senior VP Manufacturing, MedImmune LLC USA	Dr Alain Bouckenooghe, Regional Head Asia Pacific, Sanofi Pasteur, Singapore	Dr. Rainer Henning Chief Executive Officer Biomay AG USA
Dr. Florian Schodel Global Head Philimmune LLC USA	Dr. Daniel H. Zimmerman Senior VP & Head CEL-SCI Corporation USA	Dr. Charles MY Lim CEO Asia Pacific & China BIA Separations Co. Ltd. Austria
Dr. Scott M. Wheelwrigh VP&COO Innovent Biologics Inc USA	Dr. Li Shi CEO Zerun Biotechnology China	Dr. Erich Hugo Cerny CSO Chilka Limited Switzerland
Dr. Mariano Young Jr. Director Pfizer Inc China	Dr. Jean-Denis SHU Medical Director Sanofi Pasteur China	Dr. Malcolm E Thomas President & CEO Arbovax, Inc. USA
Dr. Dexiang Chen Senior Technical Officer PATH USA	Dr. Amy J Weiner Senior Program Officer Bill Melinda Gates Foundation USA	Dr. Shohreh Issazadeh-Navikas Professor University of Copenhagen Denmark
Dr. Linong Zhang Deputy Director Sanofi Pasteur Biologics Co. USA	Dr. Klaus Hermansen Senior Vaccine & Process Specialist NNE Pharmaplan Denmark	Dr. Pramod Srivastava Professor University of Connecticut Health Center USA
Dr. Mei X. Wu Associate Professor Harvard Medical School USA	Dr. Yao Zhi Q Director HCV/HIV Program East Tennessee State University USA	Dr. Hua-Ji Qiu Professor Chinese Academy of Agricultural Sciences China
Dr. Lili Sui Fast Trak China Leader GE Healthcare, Lifesciences China	Dr. Timm C. Harder Professor O.I.E., FAO & National Reference Laboratory Germany	Dr. Zhen F. Fu Professor University of Georgia USA
Dr. Jianzhu Chen Professor The David H. Koch Institute for Integrative Cancer Research USA	Dr. Yuanan Lu Professor University of Hawaii USA	Dr. Kejian Yang Vice President, Virology and Vaccine Biomedical Research Models, Inc. USA
Dr. Wenzhi Xue Sr. Group Leader, Biological R&D, Merck Animal Health USA	Dr. Tyler Martin President & Chief Medical Officer Dynavax Technologies USA	Dr. Rudolf Valenta Professor Medical University of Vienna Austria
Dr. Roa Gudding Director National Veterinary Institute Norway	Dr. Pierre-Marie Borne, Public Affairs Director, DVM, Public Health Zoonoses & Food Safety, France	Dr. Nathalie Garcon, Vice President, GlaxoSmithKline Biologicals, Belgium
Dr. Leonard P. Ruiz, President, International Medica Foundation, USA	Dr. A.M. Palache, Director, Abbott Biologicals, The Netherlands	Dr. Le Sun, President & CEO, AbMax Biotechnology Co., China
Dr. Richard Walker, Director, PATH, USA	Dr. Kelly McKee, Vice President, Quintiles Transnational Corporation, USA	Dr. Richard L. Amoroso, Professor, Noetic Advanced Studies Institute, USA
Dr. Andrew A. Potter, CEO, VIDO / InterVac, Canada	Dr. Charles M. Y. Lim, CEO Asia Pacific & China, BIA Separations, Austria	Dr. Dieter Klein, Professor, University of Veterinary Medicine, Austria
Dr. Edgar M Carvalho, Professor, Federal University of Bahia, Brazil	Dr. Guang Zeng, Professor, Chinese Center for Disease Control and Prevention, China	Dr. Han Sang Yoo, Professor, Seoul National University, South Korea
Dr. Harry L.T. Mobley, Professor, University of Michigan Medical School, USA	Dr. Jude E Uzonna, Associate Professor, University of Manitoba, Canada	Dr. Niels Guldager, Senior Technology Partner, NNE Pharmaplan, Denmark
Dr. Riccardo Cortese, CEO, Okairos, Italy	Dr. Ruobing Wang, Associate Professor, University of Washington, USA	Dr. Ronald L. Thune, Professor, Louisiana State University, USA
Dr. Takashi Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences, USA	Dr. Ted M. Ross, Associate Professor, University of Pittsburgh, USA	Dr. Vladimir Motin, Associate Professor, University of Texas Medical Branch, USA
Dr. Michel De Wilde, Senior Vice President, Sanofipasteur, Belgium	Dr. John W. Shiver, Vice President & Worldwide Basic Research Franchise Head, Vaccines. Merck & Co., Inc., USA	Dr. Rahul Singhvi, CEO & President, Novavax Inc., USA
Dr. John E. Tedstrom, President & CEO, Global Business Coalition on HIV/AIDS, Tuberculosis & Malaria (GBC), USA	Dr. Wen Yumei, Academician, Chinese Academy of Engineering, China	Dr. Nathalie Garcon, Vice President , GSK Biologicals, USA
Dr. Peter H. Khoury, Vice President, Global Marketing Baxter BioScience, Vaccines, USA	Dr. Oliver Kisker, Senior Vice President, Merck KGaA, Germany	Dr. Jaap Goudsmit, Chief Scientific Officer, Crucell, The Netherlands
Dr. B. G. Rhee, Executive Vice President, Green Cross Corporate, Korea	Dr. Jerald C. Sadoff, Chief Medical Officer, Crucell, The Netherlands	Dr. Eluemuno. R. Blyden, CEO, AfriVax Inc, USA
Dr. Francis E. André, Ex-Vice President, GlaxoSmithKline Biologicals, Belgium	Dr. Frank J. Malinoski, Chief Medical Officer, Liquidia Technologies, USA	Dr. Malcolm Thomas, President and CEO, Arbovax, Inc., USA
Dr. Mark R Alderson, Director, Pneumococcal Vaccine Project, PATH, USA	Dr. Thomas Muster, CEO, AVIR Green Hills Biotechnology, Austria	Dr. Robert Lambkin-Williams, CEO, Retroscreen Virology Limited, UK
Dr. Bernd Eisele, CEO, VPM Inc., Germany	Dr. Jose M. Galarza, CEO, TechnoVax, Inc., USA	Dr. Jeanne Novak, President and Chief Executive Officer, CBR International Corporation, USA
Dr. Tomas Jelinek, Medical Director, Berlin Centre for Travel & Tropical Medicine, Germany

Exhibition and Poster

　WCV-2023 provides an ideal platform to showcase your novel technologies and products. It is developed to offer comfort to delegates while maximizing exhibitor exposure, the coffee breaks and poster sessions will all take place in the exhibition area promoting frequent repeated opportunities for delegates to visit the exhibits.
Why Reserve a Booth at WCV-2023
• To Meet Face-to-Face with the International Movers and Shakers
• To Meet with Key Decision Marker
• To Explore Business Opportunities
• To Spotlight Advanced Technologies and Their Scientific and Commercial Applications
• To Take Advantage of the Conference's Captive Audience and Networking Opportunities within the Exhibition Hall

Introduction of Dalian

　Dalian — the "Northern Pearl" and summer resort of China, compared to ancient capital cities such as Beijing, Xian, Nanjing or Xi’an, is a young city with only a 100-year history. Dalian is the most relaxed and livable city in Northeast China. In many parts of China, economic prosperity comes at the price of clean air and charm. Not so in Dalian, whose natural blessings are its biggest asset. Tree-lined, hilly streets, dotted colonial architectures, an impressive coastline with beaches, as well as its prosperous town, have made it being dubbed as the "Hong Kong of the North China". It is one of the three Best Tourism Cities (2006), along with Hangzhou and Chengdu, recognized by the National Tourism Administration.

Online Registration

Earlybird Registration Now

News Released